Shots:

• Codiak to receive $65M of in-kind manufacturing services for its clinical-stage programs and hold its pipeline of therapeutic candidates along with exosome engineering and loading technologies
• Lonza will obtain global access and sub-licensable rights of Codiak's high-throughput perfusion-based cGMP process for exosome manufacturing
• The companies established a center of excellence to develop exosome manufacturing & technologies. Additionally, Codiak has accelerated two engineered exosome therapeutic candidates to move into clinical studies & plans an IND submission for a third candidate in Q4’21

Ref: Globe Newswire | Image: Lonza